Cover Image
市場調查報告書

新陳代謝相關的各種合作契約:契約條件・合意內容

Global Metabolic Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 250301
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
新陳代謝相關的各種合作契約:契約條件・合意內容 Global Metabolic Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告,調查分析2007年以後新陳代謝相關的各種合作契約,彙整各種契約的近年動向、大型契約及大型醫藥品業者的契約概要、契約區分・開發階段・技術區分・適應症區分別的指南等,由下列摘要形式闡述。

報告摘要

第1章 簡介

第2章 新陳代謝相關的各種契約動向

  • 簡介
  • 過去數年新陳代謝相關的合作
  • 大型藥廠的契約活動
  • 對新陳代謝相關事業不積極的大型藥廠
  • 新陳代謝相關的合作:契約類型別
  • 新陳代謝相關的合作:產業部門別
  • 新陳代謝相關的合作:開發階段別
  • 新陳代謝相關的合作:技術類型別
  • 平均契約期間

第3章 主要契約

  • 簡介
  • 主要契約:交易額別
  • 大型藥廠涉及的主要契約

第4章 大型藥廠的契約

  • 簡介
  • 大型藥廠的合作契約利用法
  • 企業檔案資料

第5章 契約指南

  • 簡介
  • 契約類型別
    • 資產購買
    • 讓渡
    • 大型企業的委外授權
    • 共同開發
    • 共同R&D
    • 共同銷售
    • 服務契約
    • 共同推廣
    • CRADA
    • 交叉授權
    • 開發
    • 銷售
    • 股票收購
    • 授權
    • 訴訟
    • 貸款
    • 製造
    • 市場行銷
    • 材料移轉
    • 選項
    • 促銷
    • 研究
    • 權利金融資
    • 合解相關
    • 資產分割
    • 再授權
    • 供給
    • 技術轉移
    • 終了
  • 開發階段別
    • 藥物設計
    • 製劑
    • 第I階段
    • 第II階段
    • 第III階段
    • 前臨床
    • 法規
    • 製劑
  • 技術類型別
    • 解析
    • 動物模型
    • 分析
    • 生物學化合物
    • 生物標記
    • 生物材料
    • 血液製劑
    • 細胞培養
    • 細胞治療
    • 臨床檢查
    • 裝置
    • 診斷
    • 藥物設計工具
    • DNA探針
    • 藥物傳遞
    • 促成技術
    • 設備
    • 基因治療
    • 基因體學
    • 造影
    • 移植
    • 體外模型
    • 微陣列
    • 奈米科技
    • 天然產品
    • 寡核甘酸
    • 孤兒藥
    • 包裝
    • 胜肽
    • 加工
    • 蛋白質體學
    • 放射性/化學治療
    • 重組DNA
    • 再生醫療
    • 研究服務
    • 研究提供
    • RNA治療
    • 篩檢
    • 小分子
    • 幹細胞
    • 毒性
    • 疫苗

第6章 新陳代謝相關的契約:適應症別

  • 新陳代謝
  • 肢端肥大症
  • 愛迪生病
  • 肝硬化
  • 庫欣氏症候群
  • 糖尿病
  • 脂肪肝
  • 膽石
  • 生長激素疾病
  • 甲狀腺機能亢進症
  • 性腺低能症
  • 甲狀腺功能減退症
  • 苯酮尿症
  • 肝病
  • 溶小體醣脂類儲積症
  • 營養素・維他命
  • 身材矮小症
  • 抗利尿素分泌異常症(SIADH)
  • 甲狀腺疾病

第6章 合作機會

  • 線上夥伴
  • 夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2205

‘Global Metabolic Partnering 2010-2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Metabolic Partnering 2010 to 2016’ provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Metabolic partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Metabolic partnering agreement structure
  • Metabolic partnering contract documents
  • Top Metabolic deals by value
  • Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2010. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

‘Global Metabolic Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

‘Global Metabolic Partnering 2010 to 2016’ includes:

  • Trends in Metabolic dealmaking in the biopharma industry since 2010
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 3500 Metabolic deal records
  • The leading Metabolic deals by value since 2010
  • Most active Metabolic dealmakers since 2010

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In ‘Global Metabolic Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Metabolic Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 1,000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Metabolic Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Metabolic deal trends since 2010
  • Access Metabolic deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Metabolic partner companies
  • Comprehensive access to over 750 links to actual Metabolic deals entered into by the world's biopharma companies
  • Indepth review of Metabolic deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Metabolic opportunities
  • Uncover companies actively partnering Metabolic opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

  • 2.1. Introduction
  • 2.2. Metabolic partnering over the years
  • 2.3. Metabolic partnering by deal type
  • 2.4. Metabolic partnering by industry sector
  • 2.5. Metabolic partnering by stage of development
  • 2.6. Metabolic partnering by technology type
  • 2.7. Metabolic partnering by therapeutic indication

Chapter 3 -Financial deal terms for Metabolic partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Metabolic partnering
  • 3.3. Metabolic partnering headline values
  • 3.4. Metabolic deal upfront payments
  • 3.5. Metabolic deal milestone payments
  • 3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Metabolic partnering
  • 4.3. List of most active dealmakers in Metabolic
  • 4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

  • 5.1. Introduction
  • 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Metabolic therapeutic target

Appendices

  • Appendix 1 - Directory of Metabolic deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Metabolic deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Metabolic deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Metabolic deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Metabolic partnering since 2010
  • Figure 2: Metabolic partnering by deal type since 2010
  • Figure 3: Metabolic partnering by industry sector since 2010
  • Figure 4: Metabolic partnering by stage of development since 2010
  • Figure 5: Metabolic partnering by technology type since 2010
  • Figure 6: Metabolic partnering by indication since 2010
  • Figure 7: Metabolic deals with a headline value
  • Figure 8: Metabolic deals with upfront payment values
  • Figure 9: Metabolic deals with milestone payment
  • Figure 10: Metabolic deals with royalty rates
  • Figure 11: Active Metabolic dealmaking activity- 2010 to 2016
  • Figure 12: Top Metabolic deals by value since 2010
Back to Top